A molecular motor that has been previously shown to rotate when fueled by electrons through a scanning tunneling microscope tip has been functionalized with a terarylene photochrome fragment on its rotating subunit. Photoisomerization has been performed under UV irradiation. Variable-temperature 1H NMR and UV–vis studies demonstrate the rotational motion and its braking action after photoisomerization
以前已经显示出一种分子电动机,当通过扫描隧道显微镜的尖端由电子提供燃料时,该电动机会旋转,并已在其旋转亚基上使用了亚芳基光致变色片段进行了功能化。在UV辐射下已经进行了光异构化。可变温度1 H NMR和UV-vis研究证明了光异构化后的旋转运动及其制动作用。制动作用可以通过加热来逆转。一旦获得了刚性且平面闭合的形式,在较低的温度下旋转将有效地减慢,从而使这种新型转子成为具有对电子和光的独立响应的潜在电动机。
ANTIMICROBIAL/ADJUVANT COMPOUNDS AND METHODS
申请人:Wu Fan
公开号:US20140309266A1
公开(公告)日:2014-10-16
Among other things, in general, antimicrobial and/or adjuvant compounds are provided according to Formula Ia: (Ia) in which E and R1-11 have the meanings described herein; and prodrugs and pharmaceutically acceptable salts thereof. Other formulae and methods of use are also provided.
Among other things, in general, antimicrobial and/or adjuvant compounds are provided according to Formula Ia: (Ia) in which E and R1-11 have the meanings described herein; and prodrugs and pharmaceutically acceptable salts thereof. Other formulae and methods of use are also provided.
[EN] BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE<br/>[FR] COMPOSÉS CIBLANT BRM ET PROCÉDÉS D'UTILISATION ASSOCIÉS
申请人:ARVINAS OPERATIONS INC
公开号:WO2023097031A1
公开(公告)日:2023-06-01
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel- Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
本公开涉及双功能化合物,它们可用作 SMARCA2 或 BRM(靶蛋白)的调节剂。特别是,本公开涉及双功能化合物,其一端含有与 Von Hippel- Lindau E3 泛素连接酶结合的配体,另一端含有与靶蛋白结合的分子,从而使靶蛋白靠近泛素连接酶,以实现对靶蛋白的降解(和抑制)。本公开物具有与降解/抑制靶蛋白相关的广泛药理活性。本公开的化合物和组合物可以治疗或预防因目标蛋白聚集或积聚而导致的疾病或失调。
[EN] ANTIMICROBIAL/ADJUVANT COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ANTIMICROBIENS/D'ADJUVANTS ET PROCÉDÉS ASSOCIÉS
申请人:DENOVAMED INC
公开号:WO2012116452A1
公开(公告)日:2012-09-07
Among other things, in general, antimicrobial and/or adjuvant compounds are provided according to Formula la: (Ia) in which E and R1-11 have the meanings described herein; and prodrugs and pharmaceutically acceptable salts thereof. Other formulae and methods of use are also provided.